GSA Capital Partners’s Fulgent Genetics FLGT Stock Holding History

GSA Capital Partners’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,287	Closed	-$533K	–	1863
2025 Q4	$533K	Sell	20,287 -61,198	-75%	-$1.59M	0.05%	765
2025 Q3	$1.84M	Buy	81,485 +311	+0.4%	+$6.41K	0.15%	103
2025 Q2	$1.61M	Sell	81,174 -23,641	-23%	-$461K	0.11%	198
2025 Q1	$1.77M	Buy	104,815 +85,481	+442%	+$1.46M	0.16%	103
2024 Q4	$357K	Buy	+19,334	New	+$377K	0.03%	1112
2024 Q3	–	Sell	-40,323	Closed	-$791K	–	1737
2024 Q2	$791K	Buy	+40,323	New	+$842K	0.06%	672
2023 Q4	–	Sell	-24,636	Closed	-$659K	–	1638
2023 Q3	$659K	Buy	+24,636	New	+$841K	0.06%	626
2021 Q1	–	Sell	-4,168	Closed	-$217K	–	1230
2020 Q4	$217K	Buy	+4,168	New	+$174K	0.04%	933
2020 Q2	–	Sell	-10,109	Closed	-$109K	–	770
2020 Q1	$109K	Sell	10,109 -10,491	-51%	-$146K	0.03%	883
2019 Q4	$266K	Buy	+20,600	New	+$245K	0.03%	1106
2017 Q2	–	Sell	-11,300	Closed	-$123K	–	1755
2017 Q1	$123K	Buy	+11,300	New	+$134K	0.01%	1648

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GSA Capital Partners's FLGT Position: Q1 2026 in Review

GSA Capital Partners sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 20,287 shares — an estimated $533K sold.

GSA Capital Partners first reported a position in FLGT in Q1 2017 and held it in 11 quarters. The position peaked at $1.84M in Q3 2025. 158 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

GSA Capital Partners reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 20,287 Fulgent Genetics shares in Q1 2026, an estimated $533K.
GSA Capital Partners first reported a position in Fulgent Genetics in Q1 2017 and held it in 11 quarters.
GSA Capital Partners's Fulgent Genetics position peaked at $1.84M in Q3 2025.
158 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.